RADIOBIOLOGICAL AND TREATMENT PLANNING STUDY OF A SIMULTANEOUSLY INTEGRATED BOOST FOR CANINE NASAL TUMORS USING HELICAL TOMOTHERAPY

Authors

  • ALONSO N. GUTIÉRREZ,

    1. Department of Medical Physics, School of Veterinary Medicine, University of Wisconsin, Madison, WI, 53792,
    Search for more papers by this author
  • MICHAEL DEVEAU,

    1. School of Medicine and Public Health, Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, 53792,
    Search for more papers by this author
  • LISA J. FORREST,

    1. School of Medicine and Public Health, Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, 53792,
    Search for more papers by this author
  • WOLFGANG A. TOMÉ,

    1. Department of Medical Physics, School of Veterinary Medicine, University of Wisconsin, Madison, WI, 53792,
    2. Department of Human Oncology, School of Veterinary Medicine, University of Wisconsin, Madison, WI, 53792
    Search for more papers by this author
  • THOMAS R. MACKIE

    1. Department of Medical Physics, School of Veterinary Medicine, University of Wisconsin, Madison, WI, 53792,
    2. Department of Human Oncology, School of Veterinary Medicine, University of Wisconsin, Madison, WI, 53792
    3. TomoTherapy, Inc., Madison, WI, 5717
    Search for more papers by this author

Address correspondence and reprint requests to Dr. Lisa J Forrest, at the above address. E-mail: forrestl@svm.vetmed.wisc.edu

Abstract

Feasibility of delivering a simultaneously integrated boost to canine nasal tumors using helical tomotherapy to improve tumor control probability (TCP) via an increase in total biological equivalent uniform dose (EUD) was evaluated. Eight dogs with varying size nasal tumors (5.8–110.9 cc) were replanned to 42 Gy to the nasal cavity and integrated dose boosts to gross disease of 45.2, 48.3, and 51.3 Gy in 10 fractions. EUD values were calculated for tumors and mean normalized total doses (NTDmean) for organs at risk (OAR). Normal Tissue Complication Probability (NTCP) values were obtained for OARs, and estimated TCP values were computed using a logistic dose–response model and based on deliverable EUD boost doses. Significant increases in estimated TCP to 54%, 74%, and 86% can be achieved with 10%, 23%, and 37% mean relative EUD boosts to the gross disease, respectively. NTCP values for blindness of either eye and for brain necrosis were <0.01% for all boosts. Values for cataract development were 31%, 42%, and 46% for studied boost schemas, respectively. Average NTDmean to eyes and brain for mean EUD boosts were 10.2, 11.3, and 12.1 Gy3, and 7.5, 7.2, and 7.9 Gy2, respectively. Using helical tomotherapy, simultaneously integrated dose boosts can be delivered to increase the estimated TCP at 1-year without significantly increasing the NTDmean to eyes and brain. Delivery of these treatments in a prospective trial may allow quantification of a dose-response relationship in canine nasal tumors.

Ancillary